CD274 and non-small cell lung carcinoma: Currently, a phase III clinical study (NCT04964479) in which TQB-2450 (a humanized monoclonal antibody against PD-L1) is combined with anlotinib versus pembrolizumab as a first-line treatment for advanced NSCLC patients with PD-L1 ≥ 1% is ongoing.